Pharma Mar, S.A. (0RC6.L)

73.87 +0.83 (+1.14%) As of 06:20PM BST. Market open.

Pharma Mar, S.A.

Avenida de los Reyes, 1
Pol. Industrial La Mina – Norte Colmenar Viejo
Madrid 28770
Spain
34 91 846 60 00
https://www.pharmamar.com

Sector(s): 
Industry: 
Full-time employees: 509

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Jose Maria Fernandez Sousa-Faro Ph.D.	Founder, Executive Chairman, CEO & President	294k	N/A	N/A
Mr. Pedro Francisco Fernandez Puentes	Executive Vice-Chairman	124k	N/A	N/A
Mr. Juan Carlos-Torres Carretero	Founder	N/A	N/A	1949
Ms. María Luisa de Francia Caballero	Chief Financial Officer	N/A	N/A	N/A
Mr. José Luis Moreno Martinez-Losa	Director of Capital Markets & Investor Relations	N/A	N/A	N/A
Mr. Juan Gomez Pulido	General Counsel & Secretary of the Board of Directors	N/A	N/A	N/A
Ms. Sandra Llamera Sanchez	Global Compliance Head	N/A	N/A	N/A
Ms. Lara Vadillo	Communication Director	N/A	N/A	N/A
Ms. Belén Sopesén Veramendi Ph.D.	Director of Corporate Development	N/A	N/A	N/A
Mr. Luis Rupérez Cuenca	Director of Human Resources & IT	N/A	N/A	N/A

Amounts are as of 31 December 2015, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, Italy, Germany, Ireland, France, rest of EU, the United States, and internationally. The company operates through Oncology and RNA interference segments. It develops and commercializes Yondelis for the treatment of soft tissue sarcoma and for ovarian cancer; Aplidin for treating R/R multiple myeloma; and Zepzelca for treating patients with small cell lung cancer. The company also develops PM14, which is in phase II clinical trials for the treatment of solid tumors, as well as in Phase I clinical trial for the treatment of soft tissue sarcoma and prostate cancer; PM534 that is Phase I clinical trial for treating solid tumors; Tivanisiran, which is in Phase III clinical trial for the treatment of dry eye disease; and SYL1801 that is in phase II clinical trial for treating macular degeneration. In addition, it engages in the development, production, and sale of products with therapeutic activity based on reducing or silencing gene expression. The company was incorporated in 1986 and is based in Madrid, Spain.

Corporate governance

Pharma Mar, S.A.’s ISS governance QualityScore as of 1 April 2024 is 7. The pillar scores are Audit: 3; Board: 10; Shareholder rights: 7; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.